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Characterization of impurities in cefpodoxime proxetil using LC–MSn 3231. Introduction
Cefpodoxime proxetil (Fig. 1), an ester-modiﬁed prodrug, is an
oral, broad-spectrum third generation cephalosporin antibiotic1. It
has in vitro activity against many common Gram-positive and
Gram-negative pathogens associated with common pediatric
infections, so it is a useful option for empirical therapy2. It is
listed in the United States Pharmacopeia 36th Edition3, the
European Pharmacopeia 7.0 Edition4 and the Japanese Pharmaco-
peia 15th Edition5. Different analysis methods have been devel-
oped6,7 and compared8 to measure impurities and degradation
products. Fukutsu et al.9 identiﬁed three degradation products of
cefpodoxime proxetil by high-performance liquid chromato-
graphy-hyphenated techniques. However, ICH guidelines Q3A
require that all impurities (from processing and degradation) be
identiﬁed above a certain threshold10. Yet, at this time, a
systematic study for identifying cefpodoxime proxetil impurities
is not available. Hence, we focused on identifying unknown
process impurities and degradation products in cefpodoxime
proxetil using a chromatographic system from the European
Pharmacopeia 7.0 Edition using liquid chromatography with diode
array detection (LC-DAD), multiple stage mass spectrometryFigure 1 Proposed chemical structures of(MSn), and liquid chromatography–high-resolution mass spectro-
metry (LC–HRMS) methods along with stress degradation tests,
degradation11–13 and mass fragmentation mechanisms of cepha-
losporins14–16, and related synthesis processes17,18. These studies
will inform future quality control and safety of cefpodoxime
proxetil products. We characterized 15 impurities including 4
new degradation products and 4 new process impurities, along
with 7 known impurities as identiﬁed in the European Pharmaco-
peia. We would discuss these as well as the most likely cause of
their appearance and the mass fragmentation pathways of the
impurities.2. Materials and methods
2.1. Reagents and samples
HPLC-grade acetonitrile was purchased from Thermo Fisher
Scientiﬁc (Fair Lawn, NJ). Formic acid (98.0%) was supplied by
Sigma-Aldrich Co. Ltd. (St. Louis, MO, US) and analytical-grade
hydrochloric acid (HCl), sodium hydroxide (NaOH) and hydrogen
peroxide (H2O2, 30%) were obtained from Beijing Chemical Works15 impurities and cefpodoxime proxetil.
Jin Li et al.324(Beijing, China). A milli-Q water puriﬁcation system (Millipore,
Billerica, MA) was used to further purify glass-distilled water.
Cefpodoxime proxetil RS (Batch No. 130517-200802, containing
95.9% of cefpodoxime) was provided by National Institutes for
Food and Drug Control, China. Cefpodoxime proxetil capsules
(Batch No. 130401) and bulk material (Batch No. 12072-01) were
obtained from Zhejiang Yatai Pharmaceutical Company (Zhejiang,
China). Cefpodoxime proxetil systematic RS (Batch No. 1.0) and
cefpodoxime proxetil impurity H RS (Batch No. 1.0) were pur-
chased from European Directorate for Quality Medicines (EDQM).
2.2. Reference standard and sample solutions preparation
Approximately 3 mg of cefpodoxime proxetil systematic RS was
transferred to a 10 mL volumetric ﬂask, and dissolved in 10 mL of
a mixture of water, acetonitrile and acetic acid (99:99:1, v/v/v).
This was the systematic RS solution.
Next, 3 mg of cefpodoxime proxetil impurity H RS was added
to a 10 mL volumetric ﬂask and dissolved in 10 mL of a mixture
of water, acetonitrile and acetic acid (99:99:1, v/v/v). This was the
impurity H RS solution.
Then, cefpodoxime proxetil capsule contents (50 mg) were
dissolved in 50 mL of a mixture of water, acetonitrile and acetic
acid (100%) (99:99:1, v/v/v). This was the sample solution.
Cefpodoxime proxetil bulk material (50 mg) was dissolved in
50 mL of a mixture of water, acetonitrile and acetic acid (99:99:1,
v/v/v). This was the forced degradation stock solution.
2.3. Instrumentation
The LC/MS system consisted of a 3201 S1-2 binary pump, a 3202 S1-
2 vacuum degasser, a 3014 S1-2 column heater, a 3012 S1-2 column
switch system, a 3133 S1-2 sampler from SHISEIDO (Tokyo, Japan),
an Accela PDA detector (Thermo Fisher Scientiﬁc Inc., Waltham,
MA) and a 3200Q TRAP mass detector (Applied Biosystem Inc.,
California), controlled by Analysts software (version 1.5.1).
2.4. Forced degradation study
The forced degradation stock solution was transferred and
degraded under acidic, basic, 60 1C water bath, oxidative, UV
and high-temperature conditions, separately.
Acid degradation solution: About 5 mL of stock solution was
transferred into a 25 mL volumetric ﬂask. Then, 2 mL of 0.1 mol/L
hydrochloric acid was added. This mixture was allowed to stand
for 2 h, and then the acidic solution was neutralized with 2 mL of
0.1 mol/L sodium hydroxide.
Base degradation solution: About 5 mL of stock solution was
transferred into a 25 mL volumetric ﬂask and 2 mL of 0.1 mol/L
sodium hydroxide was added and maintained for 2 h. The basic solu-
tion was then neutralized with 2 mL of 0.1 mol/L hydrochloric acid.
Oxidative degradation solution: About 5 mL of stock solution
was transferred into a 25 mL volumetric ﬂask. Then, 1.0 mL of
10% hydrogen peroxide solution was added. This mixture was
maintained for 2 h.
Water bath degradation solution: About 5 mL of stock solution
was transferred into a 25 mL volumetric ﬂask. This solution was
kept in a 60 1C water bath for 45 min, and the solution was
allowed to cool to room temperature.
UV degradation solution: About 10 mL of stock solution was
placed under UV light (254 nm) for 12 h.High-temperature degradation solution: About 100 mg of cef-
podoxime proxetil bulk material was placed in an oven at 60 1C for
2 h. Then 10 mg of the above sample was transferred into a 10 mL
volumetric ﬂask. The sample was dissolved and diluted with a
mixture of water, acetonitrile and acetic acid (99:99:1, v/v/v).
2.5. Chromatographic conditions
The analysis was carried out on a Kromasil 100-5 C18 column
(4.6 mm 150 mm, 5 μm-particle diameter). Mobile phase A con-
tained formic acid–methanol–water (1:400:600, v/v/v). Mobile phase
B contained formic acid–methanol–water (1:50:950, v/v/v). UV
detection was at 254 nm and the ﬂow rate was kept at 0.6 mL/min.
Column oven temperature was 25 1C and the data acquisition time
was 165 min. The pump mode was gradient and the program was
as follows, time (min)/A (v/v):B (v/v); T0.01/95:5, T65.0/95:5,
T145.0/15:85, T155.0/15:85, T155.1/95:5, and T165.0/95:5.
2.6. Mass spectrometry
Tuning and MSn investigation of cefpodoxime proxetil and impu-
rities was carried out using the following optimized MS conditions:
electrospray ionization (EPI) positive ionization mode, decluster
potential (DP) 50 V, entrance potential (EP) 10 V, collision energy
(CE) 40 V, curtain gas: 20.0 L/h, ion source gas 1: 65.0 L/h, ion
source gas 2: 60.0 L/h, ion spray voltage (IS): 5500 V, temperature
(TEM): 500.0 1C, and Interface heater. Enhanced MS (EMS) and
enhanced product ion (EPI) spectra were acquired from m/z 50 to m/z
1200 in 0.1 amu steps with dwell time of 2.0 s. Analyst software
(version 1.5.1) was used for data acquisition and processing.
Molecular weights of each component were deduced using proto-
nated molecular ions ([MþH]þ) and were conﬁrmed using minor
adduct ions of [MþNa]þ and [MþK]þ peaks.
High resolution-mass spectrum (HR-MS) investigation was
accomplished with a dual gradient UltiMate 3000 HPLC system
(Dionex Inc., Sunnyvale, CA) equipped with a LTQ Orbit trap XL
high resolution mass spectrometer (Thermo Fisher Scientiﬁc Inc.)
with the following MS conditions: positive ionization mode, FT
cell recording window from m/z 100 to 1200, and resolution
60,000. Data processing was performed using Perl script (Quant
Merge) software.3. Results and discussion
3.1. Impurity analysis by HPLC
Cefpodoxime proxetil bulk material and capsule solutions were
analyzed using the HPLC-DAD (Fig. 2a and b) and 15 impurity
peaks were detected from the two samples. All 15 capsule
impurities originated from cefpodoxime proxetil bulk material.
To determine the source of impurities, cefpodoxime proxetil bulk
material was degraded under alkaline, acidic, 60 1C water bath,
oxidation, high-temperature, and UV irradiation conditions, based
on published cephalosporin degradation conditions19,20. Typical
chromatograms for the different forced degradation conditions are
shown in Fig. 2c–g.
Stress tests suggested that IMP-S1, IMP-S3, IMP-S4, and IMP-
S6 originated from degradation and that IMP-S7–17 were intro-
duced during synthesis. IMP-S3 increased in the 60 1C water bath
and under high temperatures. IMP-S4 and IMP-S6 increased under
Figure 2 Typical chromatograms of cefpodoxime proxetil capsule and bulk material and degradation products under different forced degradation
conditions: (a, capsule (Batch No. 130401); b, bulk material (Batch No. ECP12072-01); c, 60 1C water bath degradation; d, high-temperature
degradation; e, oxidative degradation; f, UV degradation; and g, UVþoxidative degradation).
Characterization of impurities in cefpodoxime proxetil using LC–MSn 325UV degradative conditions. One potential impurity, IMP-S1a, was
detected after exposure to the 60 1C water bath and UV degrada-
tion conditions, and four other potential impurities were detected
under oxidative conditions (IMP-S1b–e). We have characterized
all these degradation products.
3.2. Mass fragmentation pathway of cefpodoxime proxetil
Understanding cefpodoxime proxetil fragmentation pathways can
help identify impurity structures. Cefpodoxime proxetil was
analyzed in positive ion mode ﬁrstly by direct ﬂow injection
using a methanol/water (1:1) mixture as the solvent through MSn.
Mass spectra and the cefpodoxime proxetil mass fragmentation
pathway are shown in Fig. 3a–c.
3.3. Analysis of cefpodoxime proxetil systematic RS
and impurity H RS
To rapidly identify the known impurities of cefpodoxime proxetil,
cefpodoxime proxetil systematic RS and impurity H RS obtainedfrom EDQM were analyzed. Compared to standard chromato-
grams provided by EDQM, the cefpodoxime proxetil impurity B
(I, II), C, D (I, II) peaks and impurity H (I, II) peaks were detected
and marked by the retention time and UV spectra, and identiﬁed
via LC/MS analysis. Typical chromatograms and mass spectra data
for impurities are shown in Fig. 4a and b and Table 1.
3.4. Investigation of known impurities in cefpodoxime
proxetil capsules
A total of ﬁve impurities including IMP-S1, S3 (two components
S3a and S3b), S4 and S6 were identiﬁed as known impurities by
comparing the retention times, UV spectra and MS data of the
impurities in samples with systematic RS and impurity H RS. The
typical TIC of cefpodoxime proxetil capsules is depicted in Fig. 5a.
The mass spectra of these ﬁve impurities are shown in Fig. 5b–h.
3.4.1. IMP-S1
The ions at m/z 528.4 and m/z 550.3 in the þEMS spectrum
were hypothesized to be [MþH]þ and [MþNa]þ ion peaks,
Figure 3 Mass spectra and mass fragmentation pathway of cefpodoxime proxetil (a, þEMS; b, EPI@558.1 [MþH]; and c, fragmentation pathway).
Jin Li et al.326respectively (Fig. 5b). Therefore the molecular weight of
IMP-S1 was proposed to be 527.4. This IMP-S1was identiﬁed as
Imp B diast I by comparing fragmental ion peaks at m/z 558.4 as
well as the retention time. The chemical structure is shown in Fig. 1.3.4.2. IMP-S3
There were two co-elutes in the IMP-S3 peak, including the main
peak (S3a) and a minor peak (S3b). The molecular weight of the
main component (S3a) was deduced to be 557.2 based on the ions
at m/z 558.2 [MþH]þ and m/z 580.3 [MþNa]þ (Fig. 5c). The
molecular weight of the minor component (S3b) was proposed to
be 527.4 due to the ions at 528.4 [MþH]þ and 550.3 [MþNa]þ
(Fig. 5d). IMP-S3a and IMP-S3b were identiﬁed as Imp C and Imp
B diast II, separately (Fig. 1).3.4.3. IMP-S4 and S5
The molecular weights of IMP-S4 and IMP-S5 were both deduced
to be 557.4 according to the ions at m/z 558.4 [MþH]þ and m/z
580.3 [MþNa]þ (Fig. 5e and f) compared to mass data from
cefpodoxime proxetil systematic RS, IMP-S4 and S5 were
conﬁrmed to be Imp-D diast I and Imp-D diast II, respectively
(Fig. 1).3.4.4. IMP-S15 and S16
Similar to IMP-S4 and S5, IMP-S15 and IMP-S16 were of the
same molecular weight (1114.2 Da) based on the ions at m/z
1115.3 [MþH]þ and m/z 1137.3 [MþNa]þ (Fig. 5g and h). These
impurities were deduced to be cefpodoxime proxetil dimers, Imp-
H diast I and Imp-H diast II, respectively (Fig. 1). Thus, 7
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systematic RS and Imp-H RS provided from EDQM.3.5. Investigation of unknown components in commercial
cefpodoxime proxetil samples
The 9 impurity peaks in the cefpodoxime proxetil samples aside
from the 7 reported impurities were derived from the commercialTable 1 Mass spectra data of impurities in cefpodoxime proxetil.
Peak
No.
Peak
name
Component
name
Retention
time (min)
MW Formula [M
[M
1 IMP-S1a Imp B diast Ia 46.3 527 C20H25N5O8S2 52
2 API-1 Cefpodoxime
proxetil diast I
50.1 557 C21H27N5O9S2 55
3 IMP-S3 Imp B diast IIa 56.9 527 C20H25N5O8S2 52
Imp Ca 56.9 557 C21H27N5O9S2 55
4 IMP-S4a Imp-D diast Ia 62.7 557 C21H27N5O9S2 55
5 API-2 Cefpodoxime
proxetil diast
II
68.6 557 C21H27N5O9S2 55
6 IMP-S6a Imp-D diast
IIa
76.9 557 C21H27N5O9S2 55
7 IMP-S7 Imp-Ib 87.6 687 C27H37N5O12S2 68
12 IMP-S12 Imp-J diast Ib 113.5 643 C25H33N5O11S2 64
13 IMP-S13 Imp-J-Diast
IIb
116.1 643 C25H33N5O11S2 64
15 IMP-S15 Imp-H diast Ia 122.2 1114 C42H54N10O18S4 11
16 IMP-S16 Imp-H diast
IIa
123.9 1114 C42H54N10O18S4 11
1a IMP-S1a Imp Aa 2.72 427 C15H17N5O6S2 42
1b IMP-S1b Imp K Diast Ib 20.27 573 C21H27N5O10S2 57
1c IMP-S1c Imp L Diast Ib 23.34 573 C21H27N5O10S2 57
1d IMP-S1d Imp K Diast
IIb
27.61 573 C21H27N5O10S2 57
1e IMP-S1e Imp L Diast
IIb
30.15 573 C21H27N5O10S2 57
aNote: these impurities are reported in European Pharmacopeia 7.0.
bThese unknown impurities are characterized for the ﬁrst time.
Figure 4 Typical chromatograms of impurities in cefpodoxime
proxetil systematic RS (a) and impurity H RS (b).synthesis process. A detailed elucidation was conducted on IMP-
S7, IMP-S12, and IMP-S13 based on the mass spectral data below.
3.5.1. IMP-S7
The þEMS of IMP-S7 presented ions at 688.2 [MþH]þ and 710.4
[MþNa]þ peaks (Fig. 6a) indicated a molecular weight of 687.2.
Compared to the molecular weight of cefpodoxime proxetil, the
molecular weight of IMP-S7 (130 Da) suggested an ester sub-
stituent in IMP-S4. The EPI of IMP-S7 showed that the ion at
688.2[MþH]þ was broken into a fragmental ion m/z 558 due to
the loss of a 130-Da ester group, and other fragmental ions less
than m/z 688 were all in accordance with those of cefpodoxime
proxetil. Therefore, we deduced that another 130-Da ester group
was substituted in IMP-S7.
When an esteriﬁcation reaction occurred at the cefpodoxime
acid group, the same reaction might occur at the cefotaxime group
to form by-products, according to the possible side reaction
principle of cefpodoxime proxetil; the reaction principle is shown
in Fig. 6b. The mass fragmentation pathways of IMP-S7 are shown
in Fig. 6c. IMP-S7 is deﬁned as Imp I, and its chemical structure is
shown in Fig. 1.
3.5.2. IMP-S12 and S13
The EMS of IMP-S12 revealed the presence of a m/z 644.3
[MþH]þ peak and a m/z 666.2 [MþNa]þ peak (Fig. 7a), indicating
a molecular weight of 643.4. Compared to cefpodoxime proxetil, the
molecular weight of IMP-S12 was 86 Da. The EPI at 644.3
[MþH]þ spectrum showed that the ion at m/z 644 was broken intoþH],
þNa]
Typical fragmental ion peak
8, 550 484, 440, 424, 398, 380, 241, 210, 197, 126
8, 580 526, 428, 410, 382, 324, 306, 285, 241, 225, 211, 167,
156, 126
8, 550 484, 440, 424, 398, 380, 241, 210, 197, 126
8, 580 526, 498, 482, 438, 428, 396, 378, 350, 322, 241, 210,
142, 126
8, 580 526, 428, 410, 320, 241, 211, 156, 126
8, 580 526, 428, 410, 382, 324, 306, 285, 241, 225, 211, 167,
156, 126
8, 80 526, 428, 410, 320, 241, 211, 156, 126
8, 710 600, 584, 558,526, 428, 410, 382, 277, 241, 167, 126
4, 666 612, 514, 496, 468, 382, 350, 225, 167, 125
4, 666 612, 514, 496, 468, 382, 350, 225, 167, 125
15, 1137 1083, 1051, 953, 935, 909, 761, 526, 500, 396, 352
15, 1137 1083, 1051, 953, 935, 909, 761, 526, 500, 396, 352,
8, 450 396, 368, 324, 272, 241, 210, 167, 156, 125
4, 596 556, 524, 426, 408, 394, 301, 274, 225, 156, 125
4, 596 556, 524, 426, 394, 350, 274, 225, 125
4, 596 556, 524, 426, 408, 394, 301, 274, 225, 156, 125
4, 596 556, 524, 426, 394, 350, 274, 225, 125
Figure 5 Typical TIC and mass spectra of cefpodoxime proxetil capsule (a: TIC; b: IMP-S1; c: IMP-S3a; d: IMP-S3b; e: IMP-S4; f: IMP-S6;
g: IMP-S16; and h: IMP-S17).
Jin Li et al.328an ion at m/z 612 with the loss of a fragmental ion at m/z 32,
suggesting that they shared the same side group at the 3rd position,
and was broken into an ion at m/z 514 with the loss of a fragmentalion at m/z130, indicating the same ester group was substituted in the
carboxyl group. Furthermore, the fragmental ion at m/z 241 from
fragmentation pathway A was present in the EPI spectrum, and the
Figure 6 Typical mass spectra, synthetic route and mass fragmentation pathway of IMP-S7 (a: mass spectra; b: synthetic route; and c: mass
fragmentation pathway).
Characterization of impurities in cefpodoxime proxetil using LC–MSn 329ion at m/z 327 was 86 Da larger than the ion at m/z 241. Thus, the
fragmental ion at m/z 76 was substituted in the side group at 7th-
position.To obtain a precise molecular composition, impurities were
analyzed by HRMS (Fig. 7b). The molecular composition of the
impurity was calculated to be C25H33N5O11S2, suggesting an
Figure 7 Typical mass spectra, HR-mass spectra, proposed synthetic route and mass fragmentation pathway of IMP-S12 and S13 (a: mass
spectra; b: HR-MS spectra; c: synthetic route; and d: mass fragmentation pathway).
Jin Li et al.330additional C4H6O2 group was present in IMP-S12 compared to
molecular cefpodoxime proxetil.
Based on cefpodoxime proxetil synthesis, we speculated that the
cefotaxime group at the 7th position reacted with an isopropanol oxy
chloride group and produced this by-product (Fig. 7c for reaction).
From the above analysis, the chemical structure of IMP-S12 waselucidated (Fig. 1). The mass spectral fragmentation pathway of IMP-
S12 is depicted in Fig. 7d.
Based on a similar elucidation step, the IMP-S13 was deduced
to be the isomer of IMP-S12 with a chiral center at the ester group,
a ﬁnding that is in accordance with the presence of two main
cefpodoxime proxetil peaks.
Characterization of impurities in cefpodoxime proxetil using LC–MSn 331As a result, IMP-S12 and IMP-S13 were deﬁned as Imp J Diast I
and Imp J II, repectively; their chemical structures are shown in Fig. 1.
3.6. Potential degradation impurities
The stress test indicated that cefpodoxime proxetil was degraded
under UV light, oxidative conditions, high temperatures and
60 1C water bath. Degradation impurities increased during
storage and transportation, affecting product quality. Therefore,
characterizing these impurities using an LC/MS method was the
next step. Five degradation impurities were identiﬁed as
described below.
3.6.1. IMP-S1a
Impurity IMP-S1a was a typical degradation impurity discovered after
exposure to the 60 1C water bath (Fig. 2c, possible degradation
process). The mass spectra of impurity IMP-S1a displayed
a molecular ion peak at m/z 428.0 [MþH]þ, and at m/z 450.0
[MþNa]þ (Fig. 8a). The molecular weight was estimated to be 427.2,
consistent with the molecular weight of cefpodoxime acid. The EPI atFigure 8 Typical mass spectra of IMP-1a, IMP-1b, IMP-1d, and IMP-
oxidative degradation; c: IMP-1b and IMP-1d; and d: IMP-1c and IMP-1em/z 428.0 of IMP-S1a showed the same fragmental ions as cefpodox-
ime acid. Hence impurity IMP-S1a is identiﬁed as cefpodoxime acid
(Imp A) and its chemical structure is shown in Fig. 1.3.6.2. IMP-S1b–e
IMP-S1b, S1c, S1d, S1e peaks were four typical degradation
impurities derived from oxidation, and these were present in
the systematic RS obtained from EDQM but without structural
elucidation. The TIC of these four impurities is shown in
Fig. 8b.
The EMS of these four impurities (IMP-S1b–e) all had ion
peaks at m/z 574.3 [MþH]þ and m/z 596.1 [MþNa]þ (Fig. 8c and
d), indicating that each was an isomer with a molecular weight of
573.2. Compared to cefpodoxime proxetil, these four oxidation
impurities were 16 Da larger, suggesting that an additional oxygen
atom was substituted in these impurities.
According to the oxidation reaction principle, the oxidation
position was deduced to locate the sulfur atom in the matrix and a
sulfoxide group was formed. The EPI spectra indicated that the
fragmentation ions of IMP-S1b and IMP-S1d were similar,1c, IMP-1e and TIC of oxidation degradation (a: IMP-1a; b: TIC of
).
Jin Li et al.332suggesting that they were a pair of oxidative products of
cefpodoxime proxetil. IMP-S1c and IMP-S1e presented similar
fragmental ions as well, differing only with ion peak intensity
compared to the former two isomers. IMP-S1c and IMP-S1e were
likely formed due to a further isomerization of IMP-S1b and IMP-
S1d at the cefotaxime group. The possible isomerization of delta 3
was excluded because there was no obvious difference in the mass
spectra among these four impurities.
To validate this deduction, a further oxidative degradation
was conducted on the UV degraded solution. The ratio of the
peak area of IMP-S1c and IMP-S1e compared to that of IMP-
S1c and IMP-S1e obtained from the product only via oxidative
degradation increased by about 30% (Fig. 2e and g), and
conﬁrmed the structural elucidation. Impurities IMP-S1c and
IMP-S1e were deduced to be the E-isomers of IMP-S1b and
IMP-S1d, respectively. As a result, IMP-S1b and IMP-S1d
were deﬁned as Imp K Diast I and Imp KII, and IMP-S1c and
IMP-S1e were deﬁned as Imp L Diast I and Imp L II,
respectively. The chemical structures of these four impurities
are shown in Fig. 1.4. Conclusion
The impurities in commercial cefpodoxime proxetil samples were
characterized based on MS/MS fragmentation pathways and
chromatographic behaviors. In total, 15 impurities were detected
in the sample. Based on published cephalosporin degradation
mechanisms, stress tests were designed and performed. The data
showed that four impurities were degradation products and 11
impurities originated from the synthesis process. In addition, ﬁve
impurities were potential degradation products. Seven known
impurities were accurately elucidated by comparison with the
mass spectra of the systematic RS and impurity H RS. Eight new
impurities were elucidated for the ﬁrst time based on the synthesis
process and the mass fragmentation pathway of cefpodoxime
proxetil. The remaining ﬁve synthetic impurities were not char-
acterized by MS/MS methods because they were in very low
concentrations. This systematic study to identify impurities in
cefpodoxime proxetil samples will assist us to improve its quality
and safety.
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